Jiudian Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 160 million yuan, down 45.2% year on year. Operating revenue was 1.29 billion yuan, down 14.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 149 million yuan, down 47.3% year on year. Net operating cash flow was 307 million yuan, up 11.4% year on year. Second-quarter operating revenue was 692 million yuan, down 15.2% year on year, and net profit attributable to the parent was 103 million yuan, down 37.9% year on year. The company said the biomedical industry is showing structural recovery and divergence, that the market share of its leading product loxoprofen sodium gel patch remains stable, and that it is continuing to advance its strategic transformation toward innovative drugs.
Hunan Jiudian Pharmaceutical Co LtdFirst-half net profit fell 45.2% and revenue dropped 14.9%.
